JPH01246220A - Remedy for glaucoma - Google Patents
Remedy for glaucomaInfo
- Publication number
- JPH01246220A JPH01246220A JP63075489A JP7548988A JPH01246220A JP H01246220 A JPH01246220 A JP H01246220A JP 63075489 A JP63075489 A JP 63075489A JP 7548988 A JP7548988 A JP 7548988A JP H01246220 A JPH01246220 A JP H01246220A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- intraocular pressure
- agent
- glaucoma
- remedy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000010412 Glaucoma Diseases 0.000 title claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 29
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 239000002075 main ingredient Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000004410 intraocular pressure Effects 0.000 abstract description 23
- 239000003889 eye drop Substances 0.000 abstract description 13
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 230000000699 topical effect Effects 0.000 abstract description 5
- 239000002775 capsule Substances 0.000 abstract description 3
- -1 amine salt Chemical class 0.000 abstract description 2
- 229910052791 calcium Inorganic materials 0.000 abstract description 2
- 239000003885 eye ointment Substances 0.000 abstract description 2
- 239000007924 injection Substances 0.000 abstract description 2
- 238000002347 injection Methods 0.000 abstract description 2
- 229910052751 metal Inorganic materials 0.000 abstract description 2
- 239000002184 metal Substances 0.000 abstract description 2
- 229910052700 potassium Inorganic materials 0.000 abstract description 2
- 229910052708 sodium Inorganic materials 0.000 abstract description 2
- 230000000881 depressing effect Effects 0.000 abstract 1
- 229940069265 ophthalmic ointment Drugs 0.000 abstract 1
- 239000003860 topical agent Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 229940012356 eye drops Drugs 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000002997 ophthalmic solution Substances 0.000 description 4
- 229940054534 ophthalmic solution Drugs 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010030043 Ocular hypertension Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
Landscapes
- Thiazole And Isothizaole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
「産業上の利用分野」
本発明は局所投与もしくは全身投与することにより眼圧
を降下させる緑内障の治療剤に関するものである。DETAILED DESCRIPTION OF THE INVENTION "Field of Industrial Application" The present invention relates to a therapeutic agent for glaucoma that lowers intraocular pressure by local or systemic administration.
「従来技術」
はその塩類（以下本化合物という）が優れた血圧降下剤
であることが知られている（特公昭６１−４１３５６号
）。しかしながら、本化合物が眼圧に対してどのような
作用を示すかについては知られておらず、この分野につ
いての応用を検討する必要があった。``Prior Art'' It is known that its salts (hereinafter referred to as the present compound) are excellent antihypertensive agents (Japanese Patent Publication No. 41356/1983). However, it is not known what effect this compound exhibits on intraocular pressure, and it was necessary to consider its application in this field.
「味題を解決するための手段」
本発明者らは本化合物が眼圧に対してどのような作用を
有するかについて検討した結果、優れた眼圧降下作用を
示し、有用な緑内障治療剤となシ得ることを見い出した
。"Means for solving the problem" The present inventors investigated the effect of this compound on intraocular pressure and found that it exhibits an excellent intraocular pressure lowering effect and is a useful glaucoma treatment agent. I found out that there are many benefits.
「発明の開示」
合物又はその塩類（本化合物）を主成分とする緑内障治
療剤に関する。本化合物における塩としてはナトリウム
、カリウム、カルシウム、マグネシウムなどの金属塩や
有機アミン塩などがあげられる。"Disclosure of the Invention" The present invention relates to a therapeutic agent for glaucoma containing a compound or a salt thereof (the present compound) as a main component. Examples of the salts of this compound include metal salts such as sodium, potassium, calcium, and magnesium, and organic amine salts.
本化合物が優れた血圧降下作用を有することはすでに知
られているが、眼圧に対する作用については知られてい
なかった。Although it is already known that this compound has an excellent antihypertensive effect, its effect on intraocular pressure was not known.
そこで、本発明者らは本化合物の眼科分野への応用を鋭
意検討した結果、薬理試股の項で述べるように、本化合
物が優れた眼圧降下作用を有しており、緑内障の治療剤
となり得ることを見い出した。Therefore, the present inventors have intensively investigated the application of this compound to the field of ophthalmology, and as a result, as described in the pharmacological test section, this compound has an excellent ocular hypotensive effect and is a therapeutic agent for glaucoma. I discovered that it can be done.
本発明の緑内障治療剤は点眼剤、眼軟膏や注射剤などの
局所用剤でも、錠剤やカプセル剤などの全身用剤のどち
らでも良い。The therapeutic agent for glaucoma of the present invention may be either a topical preparation such as eye drops, eye ointment, or injection, or a systemic preparation such as a tablet or capsule.
本発明における本化合物の投与量は治療効果の発揮でき
るものであれば良く、局所用剤では０．０１〜５チの濃
度のもの、全身用剤では１日当りの投与量が１〜３００
■のものが好ましいが、症状、年令、剤型などにより適
宜選択すればよい。The dosage of this compound in the present invention may be as long as it can exert a therapeutic effect, and for topical preparations, the dosage is 0.01 to 5%, and for systemic preparations, the daily dosage is 1 to 300%.
(2) is preferred, but it may be selected as appropriate depending on symptoms, age, dosage form, etc.
本発明製剤は剤型に応じて本化合物に必要な添加剤を加
えて調製される。例えば、点眼剤などの局所用剤であれ
ば、塩化ナトリウム、塩化カリウム、濃グリセリンなど
の等張化剤、リン酸ナトリウム、ホウ酸、モノエタノー
ルアミンなどの緩衝化剤、エデト酸ナトリウムなどの安
定化剤、塩化ベンザルコニウム、パラオキシ安息香酸エ
ステルなどの防腐剤、ポリソルベート８０などの界面活
性剤、水酸化ナトリウムなどのｐＨ調整剤などを必要に
応じて加える。又、錠剤、カプセル剤などの全身用剤で
は、乳糖、結晶セルロースなどの賦形剤、ステアリン酸
マグネシウムなどの滑沢剤、ヒドロキシプロピルセルロ
ースなどの結合剤などを必要に応じて加える。The preparations of the present invention are prepared by adding necessary additives to the present compound depending on the dosage form. For example, for topical preparations such as eye drops, tonicity agents such as sodium chloride, potassium chloride, and concentrated glycerin, buffering agents such as sodium phosphate, boric acid, and monoethanolamine, and stabilizers such as sodium edetate are used. A preservative such as a curing agent, benzalkonium chloride or paraoxybenzoic acid ester, a surfactant such as polysorbate 80, a pH adjuster such as sodium hydroxide, etc. are added as necessary. For systemic preparations such as tablets and capsules, excipients such as lactose and crystalline cellulose, lubricants such as magnesium stearate, and binders such as hydroxypropylcellulose may be added as necessary.
次に本発明の製剤例を実施例として示す。Next, formulation examples of the present invention will be shown as examples.
「実施例」
実施例１（点眼液）
処方 １００−中
本化合物 １．Ｏｆ塩化ナナト
リウム ０．９２水酸化ナトリウム
適量
滅菌精製水
製法
滅菌精製水８０ｍ／に本化合物１．Ｏｆｉ！ 、塩化ナ
トリウム０．９ｙを加えた後、水酸化ナトリウムを用い
てｐＨを７に調整した。滅菌精製水を加えて全量を１０
０−とした。"Example" Example 1 (eye drops) Prescription 100-Nakamoto compound 1. Of Sodium Chloride 0.92 Sodium Hydroxide
Appropriate amount of sterilized purified water production method Add 1 of this compound to 80 m/80 ml of sterile purified water. Ofi! After adding 0.9y of sodium chloride, the pH was adjusted to 7 using sodium hydroxide. Add sterile purified water to bring the total volume to 10
It was set to 0-.
同様の方法で本化合物の０．１％、０．５％点眼液を調
製した。0.1% and 0.5% eye drops of this compound were prepared in the same manner.
実施例２（錠剤）
処方 １錠中
本化合物 １ｑ粉末乳糖
６１キ結晶セルロース
２５岬ヒドロキシプロピルセルロース
２ツステアリン酸マグネシウム １キ計
９０！
製法（１０００錠分）
本化合物１２、粉末乳糖６１ｙを混合した後、ヒドロキ
シプロピルセルロースを用いて造粒シタ。Example 2 (tablets) Prescription 1 tablet contains 1 q powdered lactose of this compound
61K crystalline cellulose
25 Misaki Hydroxypropyl Cellulose
2 tubes of magnesium stearate 1 kg total 90! Manufacturing method (for 1000 tablets) After mixing the present compound 12 and powdered lactose 61y, granulate it using hydroxypropyl cellulose.
これに結晶セルロース２５ノとステアリン酸マグネシウ
ム１ｙを加えて混合した後、６ｕφの８面の杆を用いて
打錠した。After adding and mixing 25 grams of crystalline cellulose and 1 y of magnesium stearate, the mixture was compressed into tablets using a 6uφ 8-sided rod.
薬理試醗
緑内障に対する薬物の臨床への有用性を調べるため、口
内変動による眼圧上昇に対する薬物の作用を調べる方法
やウサギに水を強制投与して誘発した高眼圧への作用を
調べる方法（Ｔｈｏｍａｓ Ｏ。Pharmacological testing In order to investigate the clinical usefulness of drugs for glaucoma, we conducted a method to investigate the effect of drugs on increased intraocular pressure due to intraoral fluctuations, and a method to investigate the effect on ocular hypertension induced by forced administration of water to rabbits ( Thomas O.
ＭｅＤｏｎａｌｄ他： Ａｒｅｈ、０ｐｈｔｈａｌｒｎ
ｏ１． 、８２．３８１（１９６９））を用いた。MeDonald et al.: Areh, 0phthalrn
o1. , 82.381 (1969)) was used.
そこで、実施例１の点眼液を用いて本化合物の眼圧降下
作用を調べた。Therefore, using the eye drops of Example 1, the intraocular pressure lowering effect of this compound was investigated.
１）日内変動による眼圧上昇に対する作用眼圧は１日の
うちで常に一定のものではなく、日内変動があることは
良く知られている。そこで、ウサギを用い眼圧が上昇す
る時間帯を選び、本化合物によるその抑制効果を調べた
。1) Effects on increased intraocular pressure due to diurnal fluctuations It is well known that intraocular pressure is not always constant throughout the day and that it fluctuates within the day. Therefore, using rabbits, we selected a time period when intraocular pressure increases and investigated the inhibitory effect of this compound.
実験方法
使用した全てのウサギ（１群５羽）の眼圧の日内変動を
あらかじめ測定し、それを対照とした。Experimental method The diurnal fluctuations in intraocular pressure of all rabbits used (group of 5 rabbits) were measured in advance and used as a control.
実施例１に示した０、１．０．５．１．０ ％の本化合
物の点眼液と生理食塩液を各々ウサギの両眼に５０！１
点眼し、眼圧の変化を調べた。The 0, 1.0, 5, 1.0% ophthalmic solution and physiological saline solution of this compound shown in Example 1 were each administered 50!1 to both eyes of a rabbit.
The eye drops were applied to examine changes in intraocular pressure.
結果
本化合物の点眼液および生理食塩液の点眼群と各々同一
のウサギの無処置群（対照）との差を求め、その眼圧降
下の最大値を図１に示した。Results Differences between the ophthalmic solution of the present compound and the physiological saline ophthalmic solution group and the untreated group (control) of the same rabbits were determined, and the maximum value of the decrease in intraocular pressure is shown in FIG.
図１に示されているように、生理食塩液の点眼群ではそ
の効果はほとんど見られないが、本化合物の点眼群では
その濃度の増大とともに眼圧上昇抑制の効果がはっきり
と表われている。As shown in Figure 1, this effect is hardly seen in the physiological saline eye drop group, but in the eye drop group of this compound, the effect of suppressing the rise in intraocular pressure is clearly evident as the concentration increases. .
この結果から、本化合物が眼圧降下作用を有しているこ
とは明らかである。From this result, it is clear that this compound has an effect of lowering intraocular pressure.
２）水負荷誘発高眼圧への作用
実験方法
実施例１で示した本化合物の１チ点眼液および生理食塩
液を各々４羽のウサギの両眼に５０μ１点眼した後、水
を強制投与（６０■／に９）した。2) Effect on water load-induced ocular hypertension Experimental method After instilling 50 μl of each of the ophthalmic solution and physiological saline solution of the present compound shown in Example 1 into both eyes of four rabbits, water was forcibly administered ( 60/9).
水を投与後６０分まで眼圧を測定し、本化合物と生理食
塩液との比較を行なった。Intraocular pressure was measured until 60 minutes after water was administered, and the present compound and physiological saline were compared.
結果 得られた結果（８眼の平均値）を図２に示した。result The obtained results (average value of 8 eyes) are shown in FIG. 2.
図に示したように、水投与後に眼圧上昇がみられる生理
食塩液の点眼群に対して、本化合物を点眼したものでは
有意に眼圧上昇を抑制している。As shown in the figure, the increase in intraocular pressure was significantly suppressed in the eye drops of this compound compared to the physiological saline eye drop group where an increase in intraocular pressure was observed after water administration.
この実験からも本化合物の眼圧降下作用は明らかであり
、本発明の有用性を示すものである。This experiment also reveals the intraocular pressure-lowering effect of the present compound, demonstrating the usefulness of the present invention.
「発明の効果」 本発明は眼圧降下作用を有する化合物を生成障 分として配合することによシ、優れた繰向治療／＼ 剤を提供できるという効果を有するものである。"Effect of the invention" The present invention provides a compound that has an intraocular hypotensive effect. Excellent recurrent treatment by combining the ingredients This has the effect of providing a drug.
図１は日内変動による眼圧上昇に対して、本化合物の点
眼液と生理食塩液の効果を示したものである。
縦軸は対照との眼圧の差の最大値（１０眼の平均値、単
位ｗＨｇ ）を示し、横軸は点眼液の種類を示す。
図２はウサギの眼圧の時間経過を示す。
縦軸は眼圧（ｍＨｇ ）を示し、横軸は水投与時を０と
した経過時間扮）を示す。図中の記号を以下に示す。Figure 1 shows the effects of the eye drops of this compound and physiological saline on the increase in intraocular pressure due to diurnal fluctuations. The vertical axis shows the maximum difference in intraocular pressure from the control (average value of 10 eyes, unit: wHg), and the horizontal axis shows the type of eye drops. Figure 2 shows the time course of intraocular pressure in rabbits. The vertical axis shows the intraocular pressure (mHg), and the horizontal axis shows the elapsed time (from 0 when water was administered). The symbols in the figure are shown below.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7548988A JPH0778022B2 (en) | 1988-03-28 | 1988-03-28 | Glaucoma treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7548988A JPH0778022B2 (en) | 1988-03-28 | 1988-03-28 | Glaucoma treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH01246220A true JPH01246220A (en) | 1989-10-02 |
| JPH0778022B2 JPH0778022B2 (en) | 1995-08-23 |
Family
ID=13577750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP7548988A Expired - Lifetime JPH0778022B2 (en) | 1988-03-28 | 1988-03-28 | Glaucoma treatment |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0778022B2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5629345A (en) * | 1993-07-23 | 1997-05-13 | Vide Pharmaceuticals | Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure |
| US5965620A (en) * | 1993-07-23 | 1999-10-12 | Vide Pharmaceuticals | Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022167299A1 (en) | 2021-02-02 | 2022-08-11 | Inait Sa | Machine annotation of photographic images |
-
1988
- 1988-03-28 JP JP7548988A patent/JPH0778022B2/en not_active Expired - Lifetime
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5629345A (en) * | 1993-07-23 | 1997-05-13 | Vide Pharmaceuticals | Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure |
| US5965620A (en) * | 1993-07-23 | 1999-10-12 | Vide Pharmaceuticals | Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0778022B2 (en) | 1995-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5510101A (en) | Ophthalmic pharmaceutical composition containing N-acetyl-cysteine and polyvinylalcohol | |
| CA2608457C (en) | Ebselen as a prophylactic or therapeutic agent for corneal or conjunctival disorders | |
| JPS62178514A (en) | Agent for lowering intraocular pressure | |
| JPS60184013A (en) | Eye drop | |
| GB2110532A (en) | Bendazac compositions for treatment of cataract | |
| KR100192745B1 (en) | 5-methyl-isoxazole-4-carboxylic acid anhydride and 2-hydroxyethylidene-cyanoacetate acetate for the treatment of eye diseases | |
| TWI250023B (en) | Pharmaceutical composition for itch treating agent | |
| JP3527256B2 (en) | Antiallergic eye drops | |
| JPH11189533A (en) | Eye drops | |
| JPH06316519A (en) | Use of specific sulfamoyl-substituted phenethylamine derivative for suppressing corediastasis induced by medicine or reducing expanded pupil and local dose composition used therefor | |
| JPS62185014A (en) | Composite blended drug | |
| JP2002114686A (en) | Eye drop composition | |
| JPH01246220A (en) | Remedy for glaucoma | |
| JPH06500537A (en) | Use of arylhydroxyurea compounds for the treatment of atherosclerosis | |
| JPH01250321A (en) | Antiallergic eye drop | |
| KR100193406B1 (en) | Composition for the prevention and treatment of myopia | |
| JPS588013A (en) | Pharmaceutical blend for remedy of glaucoma and high intraocular pressure disease | |
| US3920824A (en) | Stable ophthalmic formulation | |
| WO2002040028A1 (en) | Antibacterial gel eye drops | |
| JPS60115520A (en) | Peripherally selective dopamine antagonist for treatment of ophthalmic hypertension | |
| JPS6143114A (en) | Eye drop for remedy of iridal and ciliary disease | |
| US3824313A (en) | Topical opthalmic composition and methods of use | |
| TW201934542A (en) | Glaucoma therapeutic agent containing FP agonist and [beta] blocker | |
| JPH06172176A (en) | Intraocular tension depressant with azimarin as essential ingredient | |
| JPH0262821A (en) | Anticatalactous agent |